Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size?

Journal of Nuclear Medicine

Volumn 46, Issue 12, 2005, Pages 1940-1945

  Wester, Hans Jürgen ^a   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; POLYMER; RADIOPHARMACEUTICAL AGENT; TRACER; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; LIGAND; OLIGOPEPTIDE;

IMAGING SYSTEM; IMMUNOGENICITY; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; INSTRUMENTATION; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); NOTE; PROTEIN BINDING; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; LIGANDS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES; POLYMERS; PROTEIN BINDING; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION;

EID: 33644873571     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Line BR, Mitra A, Nan, A, Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med. 2005;46:1552-1560.
2. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl):115S-27S.
3. Huhalov A, Chester KA. Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging. 2004;48:279-288.
4. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabeled carbohydrated somatostatin analogs: a review of the current status. Cancer Biother Radiopharm. 2004;19:231-244.
5. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234-245.
6. Stefanidakis M, Koivunen E. Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Des. 2004;10:3033-3044.
7. Breeman WA, de Jong M, Kwekkeboorn DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421-1429.
8. 18F]galacto-RGD. PLoS Med. 2005;2:244-254.
9. 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004;10:3593-3606.
10. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions-plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463-469.
11. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med. 2001;28:1555-1565.
12. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2002;2:209-226.
13. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3:319-328.
14. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-171.
15. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
16. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR-effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-284.
17. Noguchi Y, Wu J, Duncan R, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res. 1998;89:307-314.
18. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets. 2004;8:565-586.
19. Mammen M, Choi SK, Whitesides M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed. 1998;37:2754-2794.
20. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol. 2000;6:696-703.
21. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature. 1998;395:710-713.
22. Kessler H, Haupt A, Schudok M. Structural optimization of peptides for cytoprotection of rat liver cells. In: Shiba T, Sakakibara S, eds. Peptide Chemistry 1987 (Proc. Jap. Symp. on Peptide Chem., Sept. 28-Oct. 2, 1987, Kobe, Japan). Osaka, Japan: Protein Research Foundation: 1988:627-630.
23. Kessler H, Schudok M, Haupt A. Dimerization of cyclic hexapeptides: strong increase of biological activity. In: Jung G, Bayer E, eds. Peptides 1988 (Proc. 20th Europ. Pept. Symp., Sept. 4-9, 1988, Tübingen). New York, NY: Walter de Gruyter; 1989:664-666.
24. Komazawa H, Saiki I, Nishikawa N, et al. Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS. Clin Exp Metastasis. 1993;11:482-491.
25. Komazawa H, Saiki I, Aoki M, et al. Synthetic Arg-Gly-Asp-Ser analogues of the cell recognition site of fibronectin that retain antimetastatic and anti-cell adhesive properties. Biol Pharm Bull. 1993;16:997-1003.
26. Koamazawa H, Siki I, Igarashi Y, et al. The conjugation of RGDS peptide with CM-chitin augments the peptide-mediated inhibition of tumor metastasis. Carbohydrate Polymers. 1993;21:299-307.
27. Matsuoka T, Hirakawa K, Chung YS, et al. Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis. 1998;16:381-388.
28. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology n y. 1995;13:265-270.
29. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release. 2005;102:191-201.
30. Mitra A, Nan A, Ghandehari H, McNeill E, Mulholland J, Line BR. Technetium-99m-labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution. Pharm Res. 2004;21:1153-1159.
31. Haubner R, Wester H-J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439-1455.
32. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
33. Ruoshlathi E, Picrschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44:517-518.
34. Arndt T, Arndt U, Reuning U, Kessler H. Integrins in angiogenesis: implications for tumor therapy. In: Weber GF, ed. Cancer Therapy: Molecular Targets in Tumor-Host Interactions. Wymondham, Norfolk, U.K.: Horizon Bioscience, Cromwell Press: 2005:93-141.
35. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291:50-54.
36. Gurrath M, Müller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive ROD peptides. Eur J Biochem. 1992;210:911-921.
37. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
38. 3 antagonists. J Am Chem Soc. 1996;118:7461-7472.
39. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
40. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptidcs in a nude mouse model. Cancer Res. 2002;62:6146-6151.
41. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
42. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
43. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
44. Lohof E, Planker E, Mang C, et al. Carbohydrate derivatives for use in drug design: cyclic alpha(v)-selective RGD peptides. Angew Chem Int Ed. 2000;39:2761-2764.
45. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002;13:1021-1030.
46. 3 integrin antagonists. J Med Chem. 1999;42:3033-3040.
47. Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of cilengitide for treatment of glioma. London, U.K.: European Medicines Agency: July 8, 2004. EMEA/COMP/326/04.
48. Brashear KM, Hunt CA, Kucer BT, et al. Non-peptide αvβ3 antagonists. Part 5: identification of potent RGD mimetics incorporation 2-aryl β-amino acids as aspartic acid replacements. Bioorg Med Chem Lett. 2002;12:3483-3486.
49. Biltresse S, Attolini M, Dive G, Cordi A, Tucker GC, Marchand-Brynaert J. Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins αvβ′33/ α′49′49bβ′33 and in cellular adhesion tests. Bioorg Med Chem Let. 2004;12:5379-5393.
50. 18F]GBHO-2 [abstract]. J Labelled Compds Radiopharm. 2003;46(suppl):S4.
51. 18F]GBHO-2: an RGD-mimetic for non-invasive determination of avb3 expression [abstract]. Nucl Med. 2003;42:A55.
52. 123I]AZA-RGD-1: a radiolabelled RGD-mimetic for the non-invasive determination of αvb′33-integrin expression [abstract]. Eur J Nucl Med. 2001;28:1175.
53. Thumshirn G. Multivalent Cyclic RGD-Peptides and RGD-Mimetics for Application in Tumor Diagnosis and Tumor Therapy [PhD thesis]. Munich, Germany: Technische Universität; 2003.
54. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid phase peptide synthesis and chemoselective oxime ligation. Chem Eur J. 2003;9:2717-2725.
55. 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
56. Poethko T, Schottelius M, Thumshirn G, et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta. 2004;92:317-327.
57. Boturyn D, Coll J-L, Garanger E, Favrot M-C, Dumy P. Template assembled cyclopeptides as multimeric systems for integrin targeting and endocytosis. J Am Chem Soc. 2004;126:5730-5739.
58. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11-19.
59. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004;45:1776-1783.
60. 3 integrin. Protein Sci. 2002;11:1800-1812.
61. Adair BD, Yeager M. Three-dimensional model of the human platelet integrin αIIbβ3 based on electron cryomicroscopy and x-ray crystallography. Proc Natl Acad Sci U S A. 2002;99:14059-14064.
62. Schneider D, Engelman DM. Involvement of transmembrane domain interactions in signal transduction by α/β integrins. J Biol Chem. 2004;279:9840-9846.
63. Li R, Babu CR, Lear JD, Wand AJ, Bennett JS, DeGrado WF. Oligomerization of the integrin αIIbβ3: roles of the transmembrane and cytoplasmic domains. Proc Natl Acatl Sci U S A. 2001;98:12462-12467.
64. Li W, Metcalf DG, Gorelik R, et al. A push-pull mechanism for regulating integrin function. Proc Natl Acad Sci U S A. 2005;102:1424-1429.
65. Gottschalk K-E, Kessler H. A computational model of transmembrane integrin clustering. Structure. 2004;12:1109-1116.
66. Tadokoro S, Shanttil SJ, Eto K, et al. Talin binding to integrin β tails: a final common step in integrin activation. Science. 2003;302:103-106.
67. Arnold M, Cavalcanti-Adam E-A, Glass R, et al. Activation of integrin function by nanopatterned adhesive interfaces. Chem Phys Chem. 2004;5:383-388.
68. Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003;91:115-122.
69. Kok RJ, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem. 2002;13:128-135.
70. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. Doxorubicin- formaldehyde conjugates targeting alphavbeta3 integrin. Mol Cancer Ther. 2004;3:1593-1604.
71. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000;44:433-439.
72. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108:2270-2274.
73. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target. 2004;12:257-264.